Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?-Reference-Cited by-同舟云学术

Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?

Published:2021-01-01 Issue:1 Volume:39 Page:13-16
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Hussain Maha¹^ORCID,Lin Daniel²^ORCID,Saad Fred³^ORCID,Vapiwala Neha⁴,Chapin Brian Francis⁵,Sandler Howard⁶^ORCID,Evans Christopher P.⁷^ORCID,Carducci Michael A.⁸,Sachdev Sean⁹^ORCID

Affiliation:

1. Division of Hematology/Oncology, Department of Medicine, and Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

2. Department of Urology, University of Washington, Seattle, WA

3. Department of Urology, University of Montreal Hospital Center, Montreal, Quebec, Canada

4. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA

5. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston TX

6. Department of Radiation Oncology, Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA

7. Department of Urologic Surgery, University of California Davis Comprehensive Cancer Center, Sacramento, CA

8. Johns Hopkins Kimmel Cancer Center, Baltimore, MD

9. Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.02268

Reference22 articles.

1. Meeting the Healthy People 2020 Objectives to Reduce Cancer Mortality

2. Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

3. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study

4. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

5. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022;European Urology;2023-03

2. Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?;Journal of Clinical Oncology;2022-09-10

3. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021;European Urology;2022-07

4. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium;European Urology;2022-07

5. Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond;Radiotherapy and Oncology;2022-01